SCHEDULE: Meridian Venture Partners Updates ANI Pharma Stake

Meridian Venture Partners and Robert E. Brown, Jr. updated their beneficial ownership in ANI Pharmaceuticals, Inc., collectively holding 4.8% of common stock.

Summary

• Meridian Venture Partners II GP, L.P., Meridian Venture Partners II, L.P., Meridian Venture Partners II, Co., and Robert E. Brown, Jr. filed an Amendment No. 10 to their Schedule 13D.
• The filing reports beneficial ownership in ANI Pharmaceuticals, Inc. common stock, $0.0001 par value per share.
• Meridian Venture Partners entities collectively beneficially own 1,014,381 shares, representing 4.7% of the class.
• Robert E. Brown, Jr. beneficially owns an aggregate of 1,034,570 shares, representing 4.8% of the class.
• Robert E. Brown, Jr.'s ownership includes 20,189 shares with sole voting and dispositive power, and 1,014,381 shares with shared voting and dispositive power.
• The source of funds for the acquisition is listed as 'Other' (OO).

Sentiment

Score: 5

Explanation: The filing is an amendment to a Schedule 13D, indicating an update to existing beneficial ownership information. It does not contain new strategic initiatives, financial performance data, or explicit intentions that would significantly alter sentiment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides updated information on significant beneficial ownership, which can be relevant for understanding control and potential influence within ANI Pharmaceuticals, Inc.

Key Dates

Keywords

ANI Pharmaceuticals, Meridian Venture Partners, Schedule 13D, beneficial ownership, common stock, equity stake, institutional investor, Robert E. Brown Jr.